SCP-111

SCP-111 (also known as the FUROSCIX ReadyFlow Autoinjector) is a subcutaneous formulation of the loop diuretic furosemide, developed by scPharmaceuticals (a subsidiary of MannKind Corporation). It is designed for the treatment of fluid overload (edema) in patients with chronic heart failure (CHF) and chronic kidney disease (CKD). SCP-111 is a drug-device combination consisting of a pH-neutral furosemide solution delivered via a pre-filled, single-use autoinjector, allowing for rapid administration of an 80 mg dose. This formulation provides bioavailability equivalent to intravenous furosemide, enabling outpatient management of congestion. The drug's mechanism involves inhibiting the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. As of late 2025, SCP-111 is under FDA review with a PDUFA date in the third quarter of 2026.

Brand names

FUROSCIX ReadyFlow Autoinjector

Other names

FUR SCfurosemide subcutaneousfurosemide injection